Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Flexion Therapeutics Inc    FLXN

FLEXION THERAPEUTICS INC (FLXN)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/18/2018 06/19/2018 06/20/2018 06/21/2018 06/22/2018 Date
26.76(c) 27.41(c) 28.14(c) 27.1(c) 27.58(c) Last
211 294 379 544 790 127 335 650 645 326 Volume
+1.02% +2.43% +2.66% -3.70% +1.77% Change
More quotes
Financials (USD)
Sales 2018 25,2 M
EBIT 2018 -169 M
Net income 2018 -179 M
Finance 2018 181 M
Yield 2018 -
Sales 2019 123 M
EBIT 2019 -108 M
Net income 2019 -116 M
Debt 2019 20,0 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 34,0x
EV / Sales2019 8,57x
Capitalization 1 038 M
More Financials
Company
Flexion Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies.The firm specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis.It offers products under the Zilretta brand.The... 
More about the company
Surperformance© ratings of Flexion Therapeutics Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on FLEXION THERAPEUTICS INC
06/21FLEXION THERAPEUTICS INC : Submission of Matters to a Vote of Security Holders (..
AQ
06/21Flexion Therapeutics Named one of Boston Business Journal’s Best Places..
GL
06/19FLEXION THERAPEUTICS INC : Free Stock Performance Review on Zoetis and Three Add..
AC
06/15FLEXION THERAPEUTICS : Commercial supply of Zilretta supported by Alcami
AQ
06/15FLEXION THERAPEUTICS : Alcami's Extended Workbench Supports Commercial Supply of..
AQ
06/14FLEXION THERAPEUTICS : Alcami`s Extended Workbench Supports Commercial Supply of..
AQ
06/13FLEXION THERAPEUTICS : Alcami's Extended Workbench Supports Commercial Supply of..
PR
06/01Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635..
GL
05/08FLEXION THERAPEUTICS : 1Q Earnings Snapshot
AQ
05/08FLEXION THERAPEUTICS INC : Results of Operations and Financial Condition, Financ..
AQ
More news
Sector news : Bio Therapeutic Drugs
06/20GILEAD SCIENCES : GSK takes billion-dollar drug fight with Gilead to top AIDS me..
RE
06/20Roche to Buy Rest of Cancer Firm -- WSJ
DJ
06/20Latecomer Sanofi looks to catch next wave of cancer therapies
RE
06/19Alexion Uses FDA Priority-Review Voucher for Blood Disorder
DJ
06/19Roche to Pay $2.4 Billion for Full Control of Foundation Medicine -- 2nd Upda..
DJ
More sector news : Bio Therapeutic Drugs
Latest Tweets
06/21NYC Council Member Mark Levine is collecting donated items for immigrant chil..
8
06/21Flexion Therapeutics Named one of Boston Business Journal’s Best Places to Wo.. 
06/21Forbes Insights: What it takes to make IoT implementation a success: Q&A ..
19
06/20Flexion seen benefiting from Anika Therapeutics' failed Cingal study $FLXN $A..
2
06/20Janney Montgomery Scott Reiterates Buy on Flexion Therapeutics $FLXN Followin.. 
More tweets
Qtime:63
News from SeekingAlpha
06/20Gene therapy players in the green 
05/08Flexion Therapeutics (FLXN) CEO Michael Clayman on Q1 2018 Results - Earnings.. 
05/08Flexion Therapeutics beats by $0.23, misses on revenue 
05/04Permanent reimbursement for Flexion's Zilretta established in U.S. 
05/022 Attractive Biotech Stocks To Buy Now 
Chart FLEXION THERAPEUTICS INC
Duration : Period :
Flexion Therapeutics Inc Technical Analysis Chart | FLXN | US33938J1060 | 4-Traders
Technical analysis trends FLEXION THERAPEUTICS INC
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Average target price 38,6 $
Spread / Average Target 40%
EPS Revisions
Managers
NameTitle
Michael D. Clayman President, Chief Executive Officer & Director
Patrick J. Mahaffy Chairman
David A. Arkowitz Chief Financial & Accounting Officer
Neil Bodick Chief Scientific Officer
Scott D. Kelley Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
FLEXION THERAPEUTICS INC12.38%1 038
GILEAD SCIENCES-0.80%92 410
VERTEX PHARMACEUTICALS3.10%40 566
REGENERON PHARMACEUTICALS-11.70%35 172
GENMAB-3.97%9 557
SAREPTA THERAPEUTICS INC152.21%9 196